Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07214272 · ClinicalTrials.gov registry record · NA
A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing
A NA study of Skin Resurfacing, sponsored by Bausch Health Americas.
- Active
- Registry status
- NA
- Development phase
- 49
- Enrollment target
- 5
- Study locations
NCT07214272 is a NA study of Skin Resurfacing that is active but no longer recruiting, run by Bausch Health Americas. The registered enrollment target is 49 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT07214272, a NA study of Skin Resurfacing, is active but no longer recruiting, sponsored by Bausch Health Americas.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is a prospective, post-marketing (Phase 4) non-registrational single-arm, open-label, multicenter study.
Conditions Studied
Interventions
- DEVICE Fraxel® FTX Laser System
Study Locations (5)
California
- Dermatology Cosmetic Laser Associates of La Jolla, Inc. d/b/a West Dermatology Research Center - La Jolla
Florida
- Miami Dermatology & Laser Research LLC - Miami
Illinois
- Oak Dermatology, LLC - Naperville
New York
- Union Square Laser Dermatology, P.C - New York
Texas
- Dermatology and Laser Surgery Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2025-10-17 |
| Est. Completion | 2026-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07214272
The ClinicalTrials.gov registry entry for NCT07214272 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Skin Resurfacing appearing as the primary indexed condition, and to 1 intervention - of which Fraxel® FTX Laser System is the first listed.
NCT07214272 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT07214272 about?
NCT07214272 is a clinical study titled "A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing". This study is a prospective, post-marketing (Phase 4) non-registrational single-arm, open-label, multicenter study.
What is the current status of trial NCT07214272?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 49 participants. The study started on 2025-10-17. Estimated completion is 2026-09.
What conditions does trial NCT07214272 study?
This clinical trial studies the following conditions: Skin Resurfacing.
What interventions are being tested in trial NCT07214272?
The interventions under investigation include: Fraxel® FTX Laser System (DEVICE).
Who is sponsoring clinical trial NCT07214272?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07214272 being conducted?
This trial has 5 study locations across California, Florida, Illinois, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.